Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Hradec Kralove – page 9

191 clinical trials in Hradec Kralove, Czechia. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Hradec Kralove at a glance
191
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

191 trials in Hradec Kralove

Open in trial search

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Malignant melanoma

Recruiting

Study on the Effectiveness and Safety of Lifileucel and Pembrolizumab for Patients with Untreated, Unresectable, or Metastatic Melanoma

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Iovance Biotherapeutics Inc.

Partial seizures

Recruiting

Study on the Effects of Azetukalner in Patients with Focal-Onset Seizures

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Cervix carcinoma

Recruiting

Study on the Effects of Carboplatin and Cisplatin in Patients with Early-Stage, Intermediate-Risk Cervical Cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:CEEGOG z.s.

Malignant lymphoid neoplasm

Recruiting

Long-Term Follow-Up Study for Patients Treated with Idecabtagene Vicleucel or Lisocabtagene Maraleucel for Cancer

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Anti-neutrophil cytoplasmic antibody positive vasculitis

Not yet recruiting

Study of Avacopan Safety and Effectiveness in Patients with ANCA-associated Vasculitis

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Avacopan
  • Sponsor:Amgen Inc.

Colorectal cancer metastatic

Not yet recruiting

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Secondary immunodeficiency

Not yet recruiting

Study of Human Normal Immunoglobulin in Adults with Secondary Immune Deficiency after CAR T‑cell or T‑cell Redirecting Therapy for Hematologic Malignancies

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:CSL Behring LLC

Other cities in Czechia

The busiest research cities in the country

All 159 cities in Czechia

Clinical research in Hradec Kralove

What the registry says about research in the country

01 Gastrointestinal Disorders

Innovative research focusing on inflammatory bowel diseases, including studies evaluating new therapies for both ulcerative colitis and Crohn's disease. Clinical trials are investigating advanced treatments like OD-07656 and TAK-279 for managing moderate to severe cases.

  • Ulcerative Colitis Treatment
  • Crohn's Disease Management
  • Clostridioides difficile Studies

Additional research explores antibiotic optimization and novel therapeutic combinations.

02 Oncology Research

Comprehensive studies in cancer treatment, including trials for metastatic prostate cancer and advanced gastric cancers. Research focuses on innovative therapies combining targeted treatments with immunotherapy approaches.

  • Prostate Cancer Therapeutics
  • Gastric Cancer Treatment
  • Melanoma Interventions

Investigations include novel drug combinations and immunotherapy strategies.

03 Neurological Conditions

Advanced research in multiple sclerosis and Parkinson's disease, evaluating new therapeutic approaches and comparing treatment efficacies. Studies include assessments of innovative medications and comparative analyses.

  • Multiple Sclerosis Treatments
  • Parkinson's Disease Therapy
  • Stroke Management

Focus on both disease-modifying treatments and symptom management.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.